Rtw Investments Adds $2M in Stoke Therapeutics, Inc. ($STOK)

RTW Investments added 76,669 shares of STOK, boosting its holdings to over 5.6 million shares.

Written by Trueearnings · Published Jun 13, 2026, 5:37 AM EDT

Key Points

RTW Investments increased its STOK position by 76,669 shares, reaching a total of 5,623,525 shares valued at $167.7 million.
STOK shares traded around $29.82 with recent insider buying involving several executives acquiring 17,786 shares each.
Analysts maintain a positive outlook on STOK, with multiple firms setting price targets between $35 and $60.

RTW Investments has increased its stake in STOK, adding 76,669 shares to its holdings. This brings the total to 5,623,525 shares, valued at approximately $167.7 million, according to its most recent 13F filing. The filing reflects the fund's position as of the reporting period, which may not represent its current holdings.

What Changed in RTW Investments' STOK Position

RTW Investments boosted its stake in STOK by 76,669 shares, a change of about 1.4%. The fund now holds 5,623,525 shares in total. This increase suggests a continued interest in the company, with the position valued at $167.7 million based on the latest filing.

Other Institutional Activity in STOK

Several other institutional investors have also adjusted their positions in STOK. BlackRock, Inc. increased its holdings by 173,160 shares, now owning 5,385,714 shares valued at about $175.4 million. Meanwhile, FMR LLC reduced its stake by 217,254 shares, leaving it with 5,383,666 shares worth approximately $175.3 million. Redmile Group, LLC added 130,050 shares, resulting in a total of 4,164,120 shares valued at $135.6 million. Conversely, Lynx1 Capital Management LP cut its position by 641,001 shares, holding 4,763,673 shares valued at $155.1 million.

STOK Stock Snapshot

Shares of STOK traded around $29.82 recently. The company has experienced varying institutional interest, as seen in the recent 13F filings. STOK's market activity continues to be closely watched by investors and analysts alike.

Insider Buying and Selling at Stoke Therapeutics, Inc.

On June 3, 2026, several insiders, including Arthur Levin, Seth Loring Harrison, Edward MD Kaye, Arthur Tzianabos, Julie Smith, and Adrian Krainer, each purchased 17,786 shares of STOK. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

Analysts have maintained a positive stance on STOK, with several firms reiterating their buy ratings. On March 20, 2026, Canaccord Genuity maintained its buy rating with a price target of $60. BTIG reiterated a buy rating with a $39 target on March 19. Chardan Capital also maintained its buy rating, setting a target at $35 on March 18. Overall, the consensus among analysts remains favorable, with price targets ranging from $35 to $60.

Bottom Line

RTW Investments' increased stake in STOK highlights its confidence in the company, as reflected in its latest 13F filing. Investors often track such filings to gauge institutional sentiment, though they represent historical positions. The company's recent insider activity and strong analyst ratings suggest continued interest and potential growth prospects.